Pharma Capital

'All good news' from Motif Bio's Phase III clinical trial of Iclaprim, says CEO Graham Lumsden

Graham Lumsden, chief executive of Motif Bio Plc (LON: MTFB, NASDAQ:MTFB) runs Proactive through the successful completion of a phase III clinical trial of their next-generation antibiotic, Iclaprim.

The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections (ABSSSI).


View full MTFB profile

Motif Bio Plc Timeline


Motif Bio successfully raises US$25mln

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.